TG Therapeutics(TGTX) - 2024 Q3 - Quarterly Results

Exhibit 99.1 TG Therapeutics Reports Third Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance Third quarter 2024 U.S. BRIUMVI net revenue of $83.3 million Raises full year 2024 U.S. BRIUMVI net revenue target to$300 - $305 million Conference call to be held today, November 4, 2024, at 8:30 AM ET New York, NY, (November 4, 2024) – TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the third quarter of ...